Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.70−0.06 (-1.26%)
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Kyverna Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Kyverna Therapeutics's total assets was $189.44M at Sep 30, 2026. For fiscal 2025 it was $293.83M, down 3.6% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $293.83M | -3.6% |
| FY2024 | Dec 31, 2024 | $304.65M | +305.1% |
| FY2023 | Dec 31, 2023 | $75.20M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $189.44M | +1.2% |
| Q2 FY2026 | Jun 30, 2026 | $219.82M | -3.0% |
| Q1 FY2026 | Mar 31, 2026 | $257.02M | -1.4% |
| Q4 FY2025 | Dec 31, 2025 | $293.83M | -3.6% |
| Q3 FY2025 | Sep 30, 2025 | $187.16M | -44.8% |
| Q2 FY2025 | Jun 30, 2025 | $226.51M | -37.6% |
| Q1 FY2025 | Mar 31, 2025 | $260.66M | -33.2% |
| Q4 FY2024 | Dec 31, 2024 | $304.65M | +305.1% |
| Q3 FY2024 | Sep 30, 2024 | $339.20M | – |
| Q2 FY2024 | Jun 30, 2024 | $363.12M | – |
| Q1 FY2024 | Mar 31, 2024 | $389.98M | – |
| Q4 FY2023 | Dec 31, 2023 | $75.20M | – |
See a number that looks wrong?